This Phase 2 study is intended to help better understand the potential impact of SAGE-718 on the day-to-day functioning of participants with HD. Like the Dimension study, you may be eligible to participate in this trial if you are between 25 and 65 years of age and have genetically confirmed HD with pre-manifest to early-manifest presentation. Additionally, this study invites healthy volunteers to participate